Tositumomab: Difference between revisions
Jump to navigation
Jump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{| class="wikitable" border="1" width="60%" style="text-align:center" | {| class="wikitable" border="1" width="60%" style="text-align:center" | ||
|- | |- | ||
! colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[ | ! colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmacokinetics]] <ref>GlaxoSmithKline: Study No.: Hx-CD20-402</ref> | ||
|- | |- | ||
! Parameter | ! Parameter | ||
| Line 10: | Line 10: | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr) | ||
! Tositumomab | ! Tositumomab | ||
! 7.6 | ! 7.6 | ||
| Line 16: | Line 16: | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml) | ||
! Tositumomab | ! Tositumomab | ||
! 167000 | ! 167000 | ||
| Line 22: | Line 22: | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) | ||
! Tositumomab | ! Tositumomab | ||
! Ofatumumab | ! Ofatumumab | ||
| Line 28: | Line 28: | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
! 64.8 | ! 64.8 | ||
! 68 | ! 68 | ||
| Line 34: | Line 34: | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
! Tositumomab | ! Tositumomab | ||
! 32939000 | ! 32939000 | ||
| Line 40: | Line 40: | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h) | ||
! .078 | ! .078 | ||
! .017 | ! .017 | ||
| Line 46: | Line 46: | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ||
! Tositumomab | ! Tositumomab | ||
! Ofatumumab | ! Ofatumumab | ||
Revision as of 19:57, 12 December 2010
PharmacokineticsPharmacokinetics
| Anti-CD20 Monoclonal Antibody Pharmacokinetics [1] | ||||
|---|---|---|---|---|
| Parameter | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Tmax (hr) | Tositumomab | 7.6 | Rituximab | Ibritumomab |
| Cmax (ng/ml) | Tositumomab | 167000 | 205800 | Ibritumomab |
| Bioavailability (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| T1/2 (hr) | 64.8 | 68 | 206 | Ibritumomab |
| AUC (ng/ml/hr) | Tositumomab | 32939000 | Rituximab | Ibritumomab |
| Clearance (L/h) | .078 | .017 | .009 | Ibritumomab |
| IC50 (nM) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Dosage | Tositumomab | 500 mg (4th Infusion) | 325 mg/m2 (4th Infusion) | Ibritumomab |
| Metabolism | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |